Pharmacodynamics and Relative Bioavailability of Cabergoline Tablets vs Solution in Healthy Volunteers
- 1 October 1994
- journal article
- clinical trial
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 83 (10) , 1421-1424
- https://doi.org/10.1002/jps.2600831012
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Dose‐dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre studyClinical Endocrinology, 1992
- Excretion Balance and Urinary Metabolic Pattern of [3H] Cabergoline in ManDrug Metabolism and Drug Interactions, 1992
- Cabergoline in the long-term therapy of hyperprolactinemic disordersActa Endocrinologica, 1992
- Cabergoline: Long-Acting Oral Treatment of Hyperprolactinemic DisordersJournal of Clinical Endocrinology & Metabolism, 1989
- Prolactin-Lowering Effect of Acute and Once Weekly Repetitive Oral Administration of Cabergoline at Two Dose Levels in Hyperprolactinemic PatientsJournal of Clinical Endocrinology & Metabolism, 1988
- Selective and extremely long inhibition of prolactin release in man by 1-ethyl-3-(3′-dimethylaminopropyl)-3-(6′-allylergoline-8′-beta- carbonyl)-urea-diphosphate (FCE 21336).British Journal of Clinical Pharmacology, 1987
- CabergolineDrugs of the Future, 1987
- Long-Lasting Prolactin-Lowering Effect of Cabergoline, A New Dopamine Agonist, in Hyperprolactinemic PatientsJournal of Clinical Endocrinology & Metabolism, 1986
- Effects of Human Pancreatic Tumor Growth Hormone-Releasing Hormone (hpGRHl-44-NH2) on Immunoreactive and Bioactive Plasma Growth Hormone in Normal Young Men*Journal of Clinical Endocrinology & Metabolism, 1984